Alkermes plc (Nasdaq: ALKS), an Ireland-based fully-integrated, global biopharmaceutical company, announced on Thursday that it has named Christopher I Wright, MD Phd as its new director effective 24 May 2022.
Dr Wright has around three decades of drug development and clinical expertise in diseases of the central nervous system. Presently, he serves as chief medical officer at AavantiBio, Inc. and earlier served in senior medical and clinical roles at Cyclerion Therapeutics, Inc., Ironwood Pharmaceuticals, Inc., Axcella Health Inc., and Vertex Pharmaceuticals Incorporated. He has over 20 years of experience as both a practicing, board-certified neurologist at Brigham and Women's Hospital in Boston and as an associate professor of Neurology at Harvard Medical School.
Dr Wright said, 'I'm delighted to join Alkermes' board as the company seeks to develop innovative medicines and focus on real-world challenges faced by people living with complex and serious neuropsychiatric diseases. Neuroscience remains an untapped frontier in medicine and I look forward to working with the board and Alkermes' management team as they focus on advancing new medicines to help address the significant unmet needs that remain.'
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials
Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials
Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation
Genentech's Alecensa demonstrates 76% reduction in disease recurrence risk
NRx Pharmaceuticals announces presentation at 8th Annual Dawson James Conference